Original Research Paper

Genetic Analysis of Bifidobacteriaceae in a Fermented Milk and Colostrum Product in Relation to Immune Function

Marco Ruggiero

National Coalition of Independent Scholars, Battleboro, VT, United States

Abstract: This study investigates the microbial composition of a commercially available Swiss fermented milk and colostrum product with a history of use in chronic condition management since 2014. The analysis, performed using the Axiom Microbiome Array, identified a high number of targets corresponding to microbial species classified as probiotics belonging to the Bifidobacteriaceae family. The array provided 28 unique targets, each corresponding to a specific microbe. Next, the amino acid sequences of beta-galactosidase and sialidase from Bifidobacteria and humans were studied because these enzymes are responsible for the production of Gc protein-derived Macrophage Activating Factor (GcMAF) from the Gc protein that is abundant in colostrum. The Bifidobacterial enzymes showed striking functional similarities with their human counterparts. In addition, the study explores the potential health benefits of this product with a focus on GcMAF and chondroitin sulfate, a glycosaminoglycan highly represented in milk and colostrum. The high concentration of specific Bifidobacteria strains contributes to these benefits through two mechanisms: Enhanced GcMAF production and activation of chondroitin sulfate, which in turn exhibits GcMAF-like activity. These findings suggest that the Bifidobacteria-rich Swiss product could offer health benefits through these combined mechanisms.

Keywords: Bifidobacterium, DNA, Immunity, Cancer, GcMAF, Chondroitin Sulfate

Introduction

This study investigates the presence and potential health benefits of Bifidobacteria within a Swiss fermented milk and colostrum product with a history of use in chronic condition management (Ward et al., 2014; Ruggiero et al., 2014). Prior research has characterized the product's overall microbial composition, focusing on plasmids, Lactobacillaceae, Lactococaceae (Pacini and Ruggiero, 2019), and bacteriophages (Pacini and Ruggiero, 2020). In the present study, the Bifidobacteriaceae family within this product is examined as well as the role of Bifidobacterial enzymes in the endogenous production of Gc protein-derived Macrophage Activating Factor (GcMAF).

Bifidobacteria are a unique group of bacteria. They belong to the order Bifidobacteriales, which interestingly contains only one family - Bifidobacteriaceae (Biavati and Mattarelli, 2018). This is supported by findings from "The All-Species Living Tree" Project (Yarza et al., 2008). Bifidobacteria themselves are gram-positive, non-motile, and anaerobic, thriving in oxygen-free environments. Primarily found in the mammalian gastrointestinal tract (Schell et al., 2002), Bifidobacteria have also been isolated from other locations like the vagina (Albert et al., 2015) and mouth (Bifidobacterium dentium; Inchingolo et al., 2022). Notably, they are a dominant genus contributing to a healthy gut microbiota (Hidalgo-Cantabrana et al., 2017; Schell et al., 2002). Interestingly, before the 1960s, Bifidobacteria were classified as "Lactobacillus bifidus"; advancements in microbiology led to their reclassification as a distinct genus, Bifidobacterium. Various strains of Bifidobacteria have been linked to several health-supporting properties. Following is a breakdown of some of the potential benefits associated with Bifidobacteria:

- Nutrient absorption: Bifidobacteria can help break down complex carbohydrates and produce Short-Chain Fatty Acids (SCFAs) that support gut cell metabolism and promote nutrient absorption (Duranti et al., 2020)
• Immune system support: A healthy gut microbiome rich in Bifidobacteria contributes to a balanced immune response by reducing inflammation and modulating the immune system's activity (Gavzy et al., 2023)
• Diarrhea prevention: Certain Bifidobacteria strains might help prevent diarrhea caused by rotavirus or antibiotic use by competing with harmful pathogens and supporting a healthy gut barrier (Bodke and Jogdand, 2022)
• Improved bowel movements: Bifidobacteria can aid digestion and promote regular bowel movements by softening stool and increasing stool frequency (Okada et al., 2023)
• Lactose tolerance: Some Bifidobacteria strains can help break down lactose, the sugar found in milk, potentially easing symptoms in individuals with lactose intolerance (Chen et al., 2021)
• Inflammatory bowel disease: Studies suggest certain Bifidobacteria strains might play a role in reducing inflammation associated with ulcerative colitis (Yao et al., 2021)
• Atopic dermatitis (eczema): Bifidobacteria supplementation in infants might be linked to a reduced risk of developing eczema (Kim et al., 2010)
• Cancer: Bifidobacteria show anti-cancer effects in colon cancer cells (Faghfoori et al., 2021); studies using preclinical mouse models and human clinical trials have revealed a link between Bifidobacteria and the efficacy of tumor-targeting immunotherapy (Longhi et al., 2020)
• Alzheimer's disease: Treatment with Bifidobacteria can suppress amyloid β accumulation and neuro-inflammation (Wu et al., 2020)

Materials and Methods

This study investigates the microbial composition of a commercially available product called "Freeze-Dried Bravo Fermented Colostrum and Probiotic Complex" manufactured in Switzerland by Silver Spring Sgl (Arzo-Mendrisio, Ticino). The analysis was performed using the Axiom Microbiome Array; the analysis was carried out by Eurofins Microbiology Laboratories Inc (New Berlin, Wisconsin, USA). The composition of plasmids, Lactobacillaceae, Lactococcaceae, and bacteriophages in this product was previously described elsewhere (Pacini and Ruggiero, 2019; 2020). For the product under investigation, the manufacturing process involves a 48-hour fermentation of bovine milk and colostrum at room temperature, followed by freeze-drying. A separate publication details the product's nutritional facts and overall microbial composition (Antonucci et al., 2019).

The product object of these studies is manufactured in Switzerland in a Demeter-certified facility. The Demeter biodynamic certification is the oldest ecological certification for agriculture products worldwide. It signifies that a product comes from a facility adhering to the principles of biodynamic agriculture. Biodynamic agriculture has a holistic approach; it goes beyond organic farming by treating the farm or the facility as a self-contained ecosystem and emphasizes a balanced relationship between soil, plants, animals, and workers (Vaish et al., 2024). Biodynamic workers utilize unique practices like composting methods that involve specific preparations made from manure and other natural materials; planting calendars based on lunar cycles; and biodynamic sprays made from fermented plant and animal materials.

Demeter certification builds upon and surpasses the requirements for organic certification. It has more stringent regulations around imported fertility sources (manure, compost, etc.) that are encouraging on-site solutions. Weed, pest, and disease control that emphasizes preventative measures and natural solutions. Water conservation and biodiversity practices. Demeter certification provides a guarantee that the product comes from a facility committed to environmental responsibility, animal welfare, and potentially higher-quality produce.

The Axiom Microbiome Array used in this study utilizes a microarray platform, where each probe on the array is designed to detect specific DNA sequences from various microbes (Thissen et al., 2019). The Axiom Microbiome Array works by extracting DNA from the sample and this DNA is then applied to the microarray chip. If the DNA from the sample matches the sequence on a specific probe, it will bind to that probe, indicating the presence of that particular microbe in the sample. Compared to traditional methods like PCR, the Axiom Microbiome Array offers several advantages such as high throughput: It can analyze a large number of samples simultaneously, making it efficient for large-scale studies.

Comprehensiveness: It can detect a wide range of microorganisms, including known and potentially novel species. Standardized platform: The use of a standardized microarray platform ensures consistency and reproducibility in results across different laboratories. The Axiom Microbiome Array used in this study includes a total of approximately 12,000 species and uses a software program designed to analyze the composition of a microbiome in a sample, the Microbiome Detection Analysis Software (MiDAS). This program works by comparing two values for each organism: Probes Observed and Probes Expected. Probes Observed indicates the number of probes that successfully detected the target organism in the sample. Probes expected indicates the total number of probes designed to detect that specific organism. MiDAS calculates an Initial score based on this ratio. A higher score indicates a greater likelihood of the organism being present. MiDAS then uses an iterative
process to refine its analysis, MiDAS analyzes the Initial Scores and identifies the organism with the highest score as the most likely to be present. The probes specific to this chosen organism are then removed from the analysis. MiDAS then repeats the process with the remaining probes and organisms. The process of identifying the most likely organism, removing its probes, and re-analyzing until adding new organisms no longer improves the accuracy of the analysis is called Iterations. Finally, MiDAS determines positive detection based on probe intensity. A probe is considered positive if its signal is stronger than 99% of random control probes and detected in at least 20% of the probes designed for that specific target organism. In addition to the Initial Score, the program calculates the Conditional Score because the presence of other microbes in the sample could influence the detection of a particular target. The conditional score considers this by taking into account the observed probe data for all targets. It reflects the likelihood of the target being present given the context of the entire microbial community identified in the sample. The Axiom Microbiome Array demonstrates high accuracy in identifying species within mock microbial communities used for testing. It achieved a perfect 100% success rate in these controlled environments (Thissen et al., 2019).

In addition, this study investigates the characteristics of two enzymes synthesized by Bifidobacteria, beta-galactosidase (Hsu et al., 2005) and sialidase (Nishiyama et al., 2018), and compares the amino acid sequences of these enzymes with those of the corresponding human counterparts. Sequences and structures of proteins were studied using the database UniProt and, more specifically, the function designated "align" (The UniProt Consortium, 2017).

Results

The Axiom Microbiome Array demonstrated the presence of a high number of targets corresponding to microbial species that fit into the definition of probiotics and are members of the families of Bifidobacteriaceae. Table 1, shows the composition of the product as far as Bifidobacteriaceae are concerned. The array provided 28 iterations, each one corresponding to a unique target. The targets are ordered in descending sequence with those showing the highest conditional score at the top of the list. Although the assay is not quantitative, it can be deduced that a higher conditional score corresponds to a higher number of copies (Thissen et al., 2019). A higher conditional score indicates a stronger likelihood of the target microbe being present in the sample, even if other microbes are also present. A low conditional score might suggest the target microbe is less likely to be present, even if the initial score was high. This could be due to interference from other microbes or limitations in the assay. The assay uses a threshold for the ratio of the conditional score to the initial score. If this ratio is above the threshold, it increases confidence in considering the target microbe as "present" in the sample. As far as other information is concerned, in the context of the Axiom Microbiome Array, "frags" refers to DNA fragments since these probes target specific fragments of the microbial DNA, rather than the entire genome. This is because microarray technology typically works best with shorter DNA fragments for efficient hybridization with the probes and targeting specific informative fragments allows the assay to identify a wider range of microbes within a single test.

The assay is capable of precise microbe identification. For example, entry n. 7, "Bifidobacterium bifidum DSM 20456 = JCM 1255 Bifidobacterium bifidum ATCC 29521 = JCM 1255 strain ATCC 29521 draft (54 frags)" contains the following information. Bifidobacterium bifidum: This confirms the presence of this particular type of bacteria. DSM 20456 = JCM 1255 = ATCC 29521: This indicates that the assay identified DNA fragments matching multiple reference strains of Bifidobacterium bifidum. These reference strains are identified by their collection numbers in different culture collections: German Collection of Microorganisms and Cell Cultures (DSM); Japan Collection of Microorganisms (JCM); and American Type Culture Collection (ATCC). Multiple matches: The fact that the assay result lists multiple reference strains suggests that the detected DNA fragments match the characteristics of all three strains to a significant degree. This is possible because these reference strains are very closely related. However, due to the limitations of targeting specific DNA fragments, the assay might not be able to definitively distinguish between these highly similar strains. Strain ATCC 29521 (draft 54 frags): This clarifies that while the assay detected fragments matching all three reference strains, it provides additional information for the ATCC 29521 strain. Draft (54 frags): Indicates the assay did not sequence the entire genome. "54 frags" signifies that the assay detected a higher number of DNA fragments (54) matching the ATCC 29521 strain. This result strongly suggests the presence of a Bifidobacterium bifidum strain very similar to, if not exactly, Bifidobacterium bifidum ATCC 29521 in the sample. The high number of detected fragments (54) strengthens the confidence in this identification.
sequence of properties; studying the chromosome can shed light on the any unique features of this strain, such as probiotic this strain; comparing the chromosome of Bl evolutionary relationships. Identifying the genes present on gain valuable insights into genes, unique characteristics, and Bifidobacterium lactis. By studying the complete chromosome of particular strain (Bl variations in their genetic makeup and functional properties. Another example is provided by entry n. 23. "Bifidobacterium animalis subsp. lactis Bl strain ATCC 29521 draft (54 frags)
8. Bifidobacterium bifidum S17 chromosome 417.76
9. Bifidobacterium bifidum NCIMB 41171 draft (33 frags) 416.71
10. Bifidobacterium longum subsp. infantis 157F chromosome 409.13
11. Bifidobacterium longum subsp. longum 7-1B draft (34 frags) 404.93
12. Bifidobacterium longum E18 draft (7 frags) 403.64
13. Bifidobacterium longum NCC2705 chromosome 399.57
14. Bifidobacterium longum subsp. longum KACC 91563 chromosome 399.27
15. Bifidobacterium longum subsp. infantis ATCC 15697 chromosome 398.70
16. Bifidobacterium longum subsp. infantis ATCC 15697 chromosome 394.93
17. Bifidobacterium longum subsp. longum EK5 draft (28 frags) 394.09
18. Bifidobacterium animalis subsp. lactis V9 chromosome 196.17
19. Bifidobacterium animalis subsp. lactis BS 01 draft (7 frags) 186.83
20. Bifidobacterium animalis subsp. lactis BLC1 184.73
21. Bifidobacterium animalis subsp. lactis B420 chromosome 181.62
22. Bifidobacterium animalis strain RH 181.34
23. Bifidobacterium animalis subsp. lactis Bl-04 chromosome 181.34
24. Bifidobacterium animalis subsp. lactis AD011 chromosome 179.33
25. Bifidobacterium animalis subsp. lactis Bi-07 chromosome 178.60
26. Bifidobacterium longum subsp. infantis 157F chromosome 121.74
27. Bifidobacterium longum subsp. longum 7-1B draft (34 frags) 120.43
28. Bifidobacterium longum subsp. infantis ATCC 15697 chromosome 117.12

Another example is provided by entry n. 23. "Bifidobacterium animalis subsp. lactis Bl-04 chromosome". This refers to the complete set of genetic material (DNA) for a specific strain of bacteria: Bifidobacterium animalis subspecies lactis Bl-04. Animalis subsp. lactis indicates a specific subspecies within the Bifidobacterium animalis species. Subspecies are closely related groups within a species that have some unique characteristics. Bl-04 refers to a specific strain of Bifidobacterium animalis subsp. lactis. Different strains within a subspecies can have slight variations in their genetic makeup and functional properties. Chromosome refers to the single, circular DNA molecule that contains the complete genetic information for this particular strain (Bl-04) of Bifidobacterium animalis subsp. lactis. By studying the complete chromosome of Bifidobacterium animalis subsp. lactis Bl-04, it is possible to gain valuable insights into genes, unique characteristics, and evolutionary relationships. Identifying the genes present on the chromosome can reveal the potential functionalities of this strain; comparing the chromosome of Bl-04 with other Bifidobacterium strains can help identify the genetic basis of any unique features of this strain, such as probiotic properties; studying the chromosome can shed light on the evolutionary history and relationships between different Bifidobacterium strains. The complete chromosome sequence of Bifidobacterium animalis subsp. lactis Bl-04 is publicly available in online databases like the National Center for Biotechnology Information (NCBI) or GenBank.

Next, the amino acid sequences of beta-galactosidase and sialidase from Bifidobacteria (Hsu et al., 2005; Nishiyama et al., 2018) and humans were compared. These two enzymes were chosen because they are responsible for the production of GcMAF, a potent activator of macrophages, from the Gc protein that is abundant in colostrum (Ruggiero et al., 2016; Nabeshima et al., 2020); it had been previously demonstrated that the product object of this study has a very high GcMAF activity (Carter et al., 2020), possibly due to the enzymatic conversion of the Gc protein by these two enzymes released by Bifidobacteria.

Figure 1, shows the degree of identity and helix propensity of human and Bifidobacterial sialidase in the region where the two sequences were aligned.

Figure 2, shows the results of the alignment of human and Bifidobacterial sialidase where positively charged amino acids are highlighted. The rationale for the choice of positively charged amino acids lies in the interaction with the negatively charged sialic acid of GcMAF.

Figure 3, shows the results of alignment of human beta-galactosidase (Oshima et al., 1988) and beta-galactosidase from Bifidobacterium longum (Hsu et al., 2005).

The degree of identity and helix propensity in the region where the two sequences were aligned are highlighted.
Figure 4, shows the results of alignment where negatively charged amino acids are highlighted. The rationale for the choice of negatively charged amino acids lies in the interaction with the positively charged hydroxyl group of the terminal galactose residue that remains exposed once the sialic acid is removed from GcMAF.

**Fig. 1:** Results of alignment of human sialidase (Bonten et al., 1996. Upper line) and extracellular sialidase SiaBb1 from *Bifidobacterium bifidum* (Nishiyama et al., 2018)

**Fig. 2:** Results of alignment of human sialidase (Bonten et al., 1996. Upper line) and extracellular sialidase SiaBb1 from *Bifidobacterium bifidum* (Nishiyama et al., 2018). Histidine (H); Arginine (R); and Lysine (K) are highlighted
Fig. 3: Results of alignment of human beta-galactosidase (Oshima et al., 1988. Upper line) and beta-galactosidase from *Bifidobacterium longum* (Hsu et al., 2005)

Fig. 4: Results of alignment of human beta-galactosidase (Oshima et al., 1988. Upper line) and beta-galactosidase from *Bifidobacterium longum* (Hsu et al., 2005). Aspartic acid (D) and Glutamic acid (E) are highlighted
Discussion

Bifidobacteria have been known for decades for a plethora of health-supporting properties with potential therapeutic impact in a number of diseases (Chen et al., 2021). It is reasonable to state that the unequaled abundance of Bifidobacteria targets in the product that is the object of this study contributes to its health-promoting effects observed in a number of conditions ranging from cancer to viral infection (Ward et al., 2014; Ruggiero et al., 2014; Branca et al., 2015; Schwalb et al., 2016; Blythe et al., 2017; Carter et al., 2020; Blythe and Ruggiero, 2020; Zunaid et al., 2020). It is also reasonable to postulate that a major factor contributing to the health-supporting effects of the Bifidobacteria present in the product, is constituted by the ability of these bacteria to promote the endogenous production of GcMAF in milk and colostrum.

As thoroughly reviewed by Nabeshima et al. (2020), the potent immune stimulant, anti-cancer, anti-angiogenic factor GcMAF, derives from the Gc protein that is present in blood, milk, and colostrum. The concentration of Gc protein in bovine colostrum, that is in the colostrum used to manufacture the product, is close to that of human blood/plasma; 300-600 mg/L in human blood (Nabeshima et al., 2020); 250 mg/L in bovine colostrum (Ena et al., 1992). In human blood, the variant Gc1 of Gc protein is converted to GcMAF through deglycosylation operated by beta-galactosidase of activated B lymphocytes and sialidase of activated T lymphocytes. These passages of deglycosylation uncover the N-acetylgalactosamine (GalNAc) that is linked to the amino acid Threonine 420 (Thr420 or T420) present in domain III of Gc protein, thus permitting the electrostatic interaction between the positively charged GalNAc of GcMAF and the negatively charged pocket of the GcMAF receptor. The rationale for such a molecular mechanism of action based on electrostatic interactions is reinforced by the observation that the Gc2 variant of human Gc protein, a variant that has Lysine at position 420 instead of Threonine (T420K mutation) and is not glycosylated, functions as GcMAF thanks to the positive charge of Lysine. In the product that is the object of this study, the enzymatic mechanisms responsible for GcMAF generation are operated by the enzymes released by Bifidobacteria, beta-galactosidase, and sialidase, which have significant functional similarities with their human counterparts. In other words, during the process of fermentation that is performed to manufacture the product, the enzymes produced by the Bifidobacteria, convert the Gc protein of bovine milk and colostrum into the active GcMAF. Interestingly, however, the overall GcMAF activity of the products is higher than that observed with human blood-derived GcMAF (Carter et al., 2020).

The reason for this greater activity is to be found in the presence of chondroitin sulfate in milk and colostrum together with the ability of Bifidobacteria and other microbes of the product to metabolize it, thus conferring GcMAF-like activity to chondroitin sulfate. We previously hypothesized, in an article quoted by Nabeshima et al. (2020), that chondroitin sulfate has GcMAF-like activity thanks to the presence of GalNAc as one of its two constituent sugars (Ruggiero et al., 2016). It was also hypothesized that chondroitin sulfate could have been responsible for the anticancer effects observed with Coley’s vaccine (Ruggiero, 2017) as well as for the observed effects of GcMAF in autism (Ruggiero, 2016). In normal conditions, endogenous chondroitin sulfate in plasma, milk, and colostrum is complexed with proteins (Coppa et al., 2011; Ruggiero, 2021) and, therefore, its GalNAc moiety is unable to interact with the negatively charged pocket of the GcMAF receptor. However, during the process of fermentation that is performed to manufacture the product, the combined action of acidity and proteolysis from microbial proteases (Ruggiero, 2021), leads to the unmasking of GalNAc that is thus able to interact with the active site of the GcMAF receptor in a manner functionally superimposable to that of the GalNAc attached to Thr420 of GcMAF.

The GcMAF-like activity of chondroitin sulfate is further supported by the similarities of the physical properties between the sequence of alternating sugars constituting chondroitin sulfate (GalNAc and glucuronic acid) and the active site of GcMAF, that is the amino acid sequence TPT420ELAKLVNKRSE, where GalNAc is attached to T420 (Schneider et al., 2003; Gregory et al., 2010). The sequence TPT420ELAKLVNKRSE exhibits a tendency to alternate between polar and aliphatic amino acids; likewise, the repeating disaccharide units of chondroitin sulfate involve one sugar unit with aliphatic properties glucuronic acid that constitutes chondroitin sulfate and one of its two constituent sugars (Ruggiero et al., 2016). Glutamic acid (E) and glucuronic acid that constitute chondroitin sulfate have been responsible for the anticancer effects observed with Coley’s vaccine (Ruggiero, 2017) as well as for the observed effects of GcMAF in autism (Ruggiero, 2016). In normal conditions, endogenous chondroitin sulfate in plasma, milk, and colostrum is complexed with proteins (Coppa et al., 2011; Ruggiero, 2021) and, therefore, its GalNAc moiety is unable to interact with the negatively charged pocket of the GcMAF receptor. However, during the process of fermentation that is performed to manufacture the product, the combined action of acidity and proteolysis from microbial proteases (Ruggiero, 2021), leads to the unmasking of GalNAc that is thus able to interact with the active site of the GcMAF receptor in a manner functionally superimposable to that of the GalNAc attached to Thr420 of GcMAF.

The GcMAF-like activity of chondroitin sulfate is further supported by the similarities of the physical properties between the sequence of alternating sugars constituting chondroitin sulfate (GalNAc and glucuronic acid) and the active site of GcMAF, that is the amino acid sequence TPT420ELAKLVNKRSE, where GalNAc is attached to T420 (Schneider et al., 2003; Gregory et al., 2010). The sequence TPT420ELAKLVNKRSE exhibits a tendency to alternate between polar and aliphatic amino acids; likewise, the repeating disaccharide units of chondroitin sulfate involve one sugar unit with aliphatic properties glucuronic acid that constitutes chondroitin sulfate and one of its two constituent sugars (Ruggiero et al., 2016).
alternating sugars, with a resulting significantly higher probability of interaction with the GcMAF receptor. In addition, domain III of Gc protein has several negatively charged amino acids that may be implicated in its binding to the GcMAF receptor (Nabeshima et al., 2020); likewise, chondroitin sulfate is a negatively charged macromolecule and such a physical property, together with the propensity to bind to proteins (Ruggiero, 2021), might favor its binding to the GcMAF receptor. Given the uniform distribution of negative charges on the surface of chondroitin sulfate as well as its inherent flexibility, such a binding would not require site-specificity at variance with what occurs with GcMAF.

**Conclusion**

This study provides compelling evidence for the potential health benefits of Bifidobacteria-rich products observed in various conditions. The high concentration of Bifidobacteria strains likely contributes to these effects through two main mechanisms:

- **Enhanced endogenous GcMAF production:** The Bifidobacteria in the product express beta-galactosidase and sialidase enzymes, functionally similar to their human counterparts. During fermentation, these enzymes facilitate deglycosylation of the Gc protein present in bovine milk and colostrum, converting it into the active GcMAF molecule.

- **Activation of chondroitin sulfate:** The presence of chondroitin sulfate in milk and colostrum, along with its metabolism by Bifidobacteria and other microbes present in the product, contributes to the product's efficacy. Chondroitin sulfate, with its GalNAc sugar moiety, exhibits GcMAF-like activity after being freed from protein complexes by the acidic and proteolytic environment during fermentation. This process allows GalNAc to interact with the GcMAF receptor, thus amplifying the overall immune-stimulatory effects.

A limitation of this study consists in the fact that it relies on a targeted microarray technique, potentially missing uncharacterized microbes within the product's complex microbial community. Additionally, in silico analysis of enzymes may not fully represent their functionality within the dynamic gut environment. These limitations notwithstanding, the present findings suggest that the Bifidobacteria-rich product may promote health benefits through a combination of enhanced GcMAF generation and activation of chondroitin sulfate, warranting further investigation into its therapeutic potential in various disease models.

**Acknowledgment**

MR thanks the Colleagues at Silver Spring Sagl for sharing the results of the Axiom Microbiome Array for the purpose of writing this article. In addition, MR acknowledges the great work of Dr. Aldo Ruggiero, MD (1923-2006), pioneer of radiology in Prato, Italy, founder of the Studio Radiologico Ruggiero, source of boundless inspiration for this and many other scientific articles.

**Funding Information**

The author did not receive any funding for this study.

**Advisory**

No information in this study is intended or implied to be a substitute for professional medical advice, diagnosis, or treatment.

**Ethics**

This article is original and contains material that has not been submitted or published in any scientific journal. A preprint of the first submission of this article had been posted in a multidisciplinary preprint platform (Ruggiero, M. Genetic Analysis of Bifidobacteriaceae in a Fermented Milk and Colostrum Product in Relation to Immune Function. Preprints 2024, 2024051503. https://doi.org/10.20944/preprints202405.1503.v1. https://www.preprints.org/manuscript/202405.1503/v1).

**Conflicts of Interest**

MR consults for Silver Spring Sagl, the company producing the fermented product described in this study. However, he had no prior knowledge of the results of the Axiom Microbiome Array that was independently performed by Eurofins Microbiology Laboratories Inc. (New Berlin Wisconsin, USA) on a commercially available lot as part of the company's quality controls. He did not receive any remuneration for writing this article. MR is Editor-in-Chief of the American Journal of Immunology and is waived from the article-processing fee for this contribution; he receives no remuneration for his editorial work.

**References**


